Popular Fiber Supplement May Not Be Suitable for Fatty Liver Disease

A fiber supplement sitting in your medicine cabinet right now worsened liver damage in mice with non-alcoholic steatohepatitis in a 2026 study out of Edith Cowan University in Western Australia. The supplement was inulin, one of the most popular prebiotics on the market. But the damage didn’t happen because inulin is harmful in general. It happened because a NASH-damaged gut responds to inulin differently than a healthy one does, and that distinction isn’t anywhere on the label.

That condition is non-alcoholic fatty liver disease, or NAFLD (fat accumulation in the liver in people who drink little or no alcohol). The finding, published in the journal Molecular Nutrition and Food Research in April 2026, doesn’t just raise a cautionary flag about a single fiber supplement. It opens a far more interesting question about how nutrients interact with a damaged gut, and what happens when a well-intentioned intervention backfires because of who is taking it.

The research also points to a potential solution. A natural compound found in strawberries, raspberries, pomegranates, and walnuts may hold the key to changing inulin’s effect entirely. The science behind how those two things connect tells you a lot about why whole foods keep outperforming supplements, and why liver disease is so difficult to treat with a single dietary intervention.

Why NAFLD Is a Problem No One Has Solved Yet

NAFLD has become the most prevalent liver disease globally, affecting 38% of the population, according to a 2023 analysis in the Journal of Hepatology. That figure alone is striking. But what makes it urgent is the trajectory. The same research projects that the global proportion of people affected is projected to increase further, driven by rising rates of obesity and metabolic dysfunction. Without intervention, NASH (non-alcoholic steatohepatitis, the inflammatory and more severe form of NAFLD) can progress to fibrosis, cirrhosis, and even liver cancer, and the prevalence of NASH and its associated mortality is predicted to double by 2030.

The disease doesn’t discriminate neatly. About 1 in every 3 Australians has NAFLD, and a 2024 study in the Internal Medicine Journal found that Australia’s age-standardized prevalence climbed from 32.4% to 35.4% over 15 years, with women accounting for a rising share of new cases. NASH is characterized by liver inflammation and fat accumulation, and while basic NAFLD involves fat buildup in the liver, NASH additionally presents with hepatic inflammation and hepatocyte ballooning, a form of liver cell damage that can signal the beginning of scarring. About 30% of people with NAFLD will eventually develop NASH, and its potential to progress to cirrhosis and hepatocellular carcinoma has drawn significant attention.

Despite how common the condition is, the pharmacological cupboard is nearly bare. The US Food and Drug Administration has not approved any drugs for the treatment of NAFLD. Lifestyle intervention, losing weight, improving diet, increasing physical activity, remains the main management strategy. That gap is precisely why dietary supplements like inulin have attracted serious scientific attention as potential tools.

The Fiber Supplement Fatty Liver Connection: When Inulin Works Against the Liver

Inulin is a type of soluble fiber often used as a prebiotic to improve gut health, and it’s widely sold at pharmacies and health food stores for exactly that purpose. Its mechanism sounds straightforwardly beneficial: gut bacteria ferment inulin and produce short-chain fatty acids (SCFAs, small molecules the body uses for energy and metabolic regulation). Prebiotics have been speculated to be beneficial for NAFLD due to their capability to reduce gut dysbiosis, the imbalance of microbial communities in the gut that is commonly observed in NAFLD patients.

Fermentation of inulin produces primarily acetate, along with some propionate. Research published in a 2019 review found that propionate produced through fermentation of dietary fiber can reduce lipid storage in the liver, a potentially protective effect for people with fatty liver disease. On paper, the logic for inulin supplementation holds.

The ECU study, however, found something different in a mouse model of NASH specifically. The research showed that inulin led to an unexpected increase in body weight and blood glucose levels and worsened liver damage, possibly because of the imbalance of microbes in the gut associated with NASH. More precisely, histology showed worsened steatosis (fat buildup), hepatocyte ballooning, and inflammation, with fibrosis emerging in some livers.

The key phrase is “associated with NASH.” The researchers’ working explanation is that inulin’s rapid fermentation, which is normally a strength, becomes a liability when the gut microbiome is already dysbiotic. Inulin ferments rapidly, potentially causing dysbiosis in NASH and promoting inflammation. In a healthy gut, fiber fermentation supports a diverse community of beneficial bacteria. But NASH is characterized by gut dysbiosis, a skewed microbial environment where certain bacteria dominate and others are depleted. Rapid fermentation in that context can feed the wrong populations, amplifying the imbalance.

Research published in Frontiers in Pharmacology identified gut dysbiosis as playing an essential role in NAFLD development by increasing the circulation of lipopolysaccharide (LPS), a bacterial component that triggers liver inflammation when it leaks from the gut into the bloodstream. That inflammatory cycle is what inulin, in a NASH-specific gut environment, appears to potentially accelerate rather than interrupt.

This doesn’t mean fiber is harmful for NAFLD in general. The ECU finding applies specifically to inulin taken as an isolated supplement in the context of established NASH, not to dietary fiber from whole foods or other fiber types. Not all fiber supplements carry the same risk; psyllium (the fiber in Metamucil) may be safer, with the ECU study flagging fermentable inulin specifically.

The Compound in Berries and Walnuts That Changed the Result

The more actionable finding from the ECU research involves a polyphenol (a type of plant-based antioxidant compound) called ellagic acid. Found naturally in strawberries, raspberries, pomegranates, walnuts, and pecans, ellagic acid has antioxidant and anti-inflammatory properties that researchers have been studying in the context of liver disease for several years.

When ellagic acid and inulin were combined in the mouse NASH model, the 2026 study published in Molecular Nutrition and Food Research found they significantly reduced steatosis and hepatocyte ballooning, the two damage markers that had worsened in the inulin-alone group. The combined treatment didn’t simply add ellagic acid’s benefits on top; it specifically neutralized the adverse effects that inulin alone produced.

The likely mechanism runs through the gut microbiome. While ellagic acid significantly improved liver health, the combined treatment primarily neutralized the adverse effects of inulin rather than enhancing the core efficacy of ellagic acid. Ellagic acid is broken down by gut bacteria into compounds called urolithins, metabolites that research suggests have hepatoprotective (liver-protecting) effects. Ellagic acid boosts beneficial urolithins via gut microbes, helping to balance the gut-liver axis, and that microbiome-stabilizing effect appears to counteract inulin’s tendency to amplify dysbiosis in NASH.

Ellagic acid’s benefits are not uniform across individuals. A 2025 study in Food & Function found that the protective effects of ellagic acid on NAFLD mice varied considerably based on the individual’s ability to produce urolithins, which itself depends on the composition of their gut microbiota. In practical terms: the same dose of ellagic acid from the same food source can do more for one person’s liver than another’s, depending on which bacteria they carry. That’s a meaningful caveat for anyone looking to translate this research into a dietary strategy.

Human Evidence on Ellagic Acid

The mouse model findings get support from human trial data. A 2025 randomized double-blind clinical trial published in BMC Complementary Medicine and Therapies assigned 44 NAFLD patients to either 180 mg of ellagic acid daily or a placebo for eight weeks. At the end of the study, mean levels of insulin, insulin resistance, triglycerides, LDL cholesterol, liver enzymes (AST, ALT, ALP, GGT), and oxidative stress markers were significantly decreased in the intervention group. The researchers concluded that ellagic acid could be used as a supplemental therapy alongside standard treatment plans for NAFLD.

A separate clinical trial, also using the 180 mg daily dose over eight weeks, found that ellagic acid reduced inflammatory markers including IL-6 and TNF-alpha, while also increasing adiponectin, a hormone that helps regulate fat metabolism and insulin sensitivity. Ellagic acid can be utilized as an effective therapeutic intervention to reduce complications from NAFLD, the researchers concluded in the Journal of Nutrition and Food Security.

Both of these human trials involved small sample sizes, and most ellagic acid research still relies on animal models. The 2026 ECU study was conducted in mice, which means its specific findings about the inulin-ellagic acid combination have not yet been tested in people with NASH. Associate Professor Lois Balmer, who led the ECU research, said that “this research reinforces the idea that diet matters, not just what we eat, but how different nutrients interact in the body,” with human trials being the necessary next step for the inulin-ellagic acid combination specifically.

Read More: The Link Between Vitamin D Deficiency and Fatty Liver

What This Means for You

If you have NAFLD or NASH and take inulin supplements to support your gut health, the ECU research gives you a concrete reason to discuss that habit with your doctor. The concern isn’t fiber broadly; it’s isolated, rapidly-fermented inulin in the specific context of a dysbiotic NASH gut. Getting your fiber from whole foods (vegetables, legumes, whole grains) remains well-supported for metabolic and liver health. If you want to continue using a fiber supplement, psyllium husk is a less fermentable alternative that the current evidence doesn’t flag in the same way.

For ellagic acid, eat the foods that contain it. Strawberries, raspberries, pomegranates, walnuts, and pecans are all meaningful dietary sources, and the human trial data supports a benefit at 180 mg daily, an amount achievable through a combination of these foods. Whether a concentrated ellagic acid supplement offers any additional advantage over whole-food sources remains an open question, particularly given that your ability to convert ellagic acid into protective urolithins depends on your individual gut microbiome. The broader lesson from the ECU research is that the gut of someone with NASH doesn’t respond to nutrients the same way a healthy gut does, and a supplement designed for a healthy microbiome can produce a very different result in one that’s already compromised. That’s the kind of specificity that labels and general wellness advice rarely capture, and it makes the conversation with your doctor more important than any individual supplement decision.

Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.